Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.28−0.22 (-2.37%)
Close on Nov 17, 2026Market cap $596.89MP/E –Yield –
Cullinan Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cullinan Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$218.81M. For fiscal 2025 it was -$241.65M. The highest annual figure on record is $144.65M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$241.65M | – |
| FY2024 | Dec 31, 2024 | -$196.92M | – |
| FY2023 | Dec 31, 2023 | -$191.09M | -232.1% |
| FY2022 | Dec 31, 2022 | $144.65M | – |
| FY2021 | Dec 31, 2021 | -$67.95M | – |
| FY2020 | Dec 31, 2020 | -$60.34M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$52.60M | – |
| Q2 FY2026 | Jun 30, 2026 | -$57.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$53.70M | – |
| Q4 FY2025 | Dec 31, 2025 | -$55.26M | – |
| Q3 FY2025 | Sep 30, 2025 | -$55.60M | – |
| Q2 FY2025 | Jun 30, 2025 | -$75.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$55.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$55.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$48.86M | – |
| Q2 FY2024 | Jun 30, 2024 | -$50.03M | – |
| Q1 FY2024 | Mar 31, 2024 | -$42.99M | – |
| Q4 FY2023 | Dec 31, 2023 | -$45.49M | – |
| Q3 FY2023 | Sep 30, 2023 | -$45.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.61M | -115.7% |
| Q1 FY2023 | Mar 31, 2023 | -$62.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.77M | – |
| Q2 FY2022 | Jun 30, 2022 | $239.68M | – |
| Q1 FY2022 | Mar 31, 2022 | -$32.66M | -2480.2% |
| Q4 FY2021 | Dec 31, 2021 | -$34.35M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.38M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.60M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$29.17M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.54M | – |
See a number that looks wrong?